Sodium perrhenate
CAS: 13472-33-8
Rif. 3D-NAA47233
1g | Fuori produzione | ||
5g | Fuori produzione | ||
10g | Fuori produzione | ||
25g | Fuori produzione | ||
50g | Fuori produzione |
Informazioni sul prodotto
- Perrhenic acid (HReO<sub>4</sub>), sodium salt
- Perrhenic acid(HReO4), sodium salt (8CI)
- Rhenate (ReO41-), sodium (1:1), (T-4)-
- Rhenate (ReO41-), sodium, (T-4)-
- Rhenate (ReO<sub>4</sub><sup>1-</sup>), sodium (1:1), (T-4)-
- Rhenate (ReO<sub>4</sub><sup>1-</sup>), sodium, (T-4)-
- Rhenate(Reo4(sup 1-)), sodium, (T-4)- (9CI)
- Rhenium sodium oxide (ReNaO<sub>4</sub>)
- Rhenium(VII) sodium oxide
- Sodium Oxido(Trioxo)Rhenium
- Vedi altri sinonimi
- Sodium perrhenate (NaReO<sub>4</sub>)
- Sodium rhenate
- Sodium tetraoxorhenate(1-)
- Sodium perrhenate (NaReO4)
- Perrhenic acid (HReO4), sodium salt
Sodium perrhenate is a drug that is used for the treatment of cancer. It has been shown to be an effective drug for treating tumors in mice. This drug works by binding to a monoclonal antibody and targeting the tumor cells. The uptake of sodium perrhenate into the tumor cells can be increased by alkoxy radicals, which are generated internally as a result of oxygen metabolism. The pharmacokinetic properties of sodium perrhenate also make it a good candidate for treating tumors because it is stable and readily penetrates the blood-brain barrier. Sodium perrhenate also has been shown to have anticancer activity against various types of tumors, including those that are resistant to chemotherapy or radiation therapy.